TY - JOUR T1 - Comparison of antibody responses to SARS-CoV-2 variants in Australian children JF - medRxiv DO - 10.1101/2022.08.12.22278705 SP - 2022.08.12.22278705 AU - Zheng Quan Toh AU - Nadia Mazarakis AU - Jill Nguyen AU - Rachel A. Higgins AU - Jeremy Anderson AU - Lien Anh Ha Do AU - David P. Burgner AU - Nigel Curtis AU - Andrew C. Steer AU - Kim Mulholland AU - Nigel W. Crawford AU - Shidan Tosif AU - Paul V Licciardi Y1 - 2022/01/01 UR - http://medrxiv.org/content/early/2022/08/13/2022.08.12.22278705.abstract N2 - There is limited understanding of antibody responses in children across different SARS-CoV-2 variants. As part of an ongoing household cohort study, we assessed the antibody response among unvaccinated children infected with Wuhan, Delta or Omicron variants, as well as vaccinated children with breakthrough Omicron infection, using a SARS-CoV-2 S1-specific IgG assay and surrogate virus neutralisation test (sVNT). Most children infected with Delta (100%, 35/35) or Omicron (81.3%, 13/16) variants seroconverted by one month following infection. In contrast, 37.5% (21/56) children infected with Wuhan seroconverted, as previously reported. However, Omicron-infected children (GMC 46.4 BAU/ml; sVNT % inhibition: 16.3%) mounted a significantly lower antibody response than Delta (435.5 BAU/mL, sVNT=76.9%) or Wuhan (359.0 BAU/mL, sVNT=74.0%). Vaccinated children with breakthrough Omicron infection mounted the highest antibody response (2856 BAU/mL, sVNT=96.5%). Our findings suggest that despite a high seroconversion rate, Omicron infection in children results in lower antibody levels and function compared with Wuhan or Delta infection or with vaccinated children with breakthrough Omicron infection. Our data have important implications for public health measures and vaccination strategies to protect children.Competing Interest StatementNWC received funding from the National Institute of Health for influenza and COVID-19 research.Funding StatementRoyal Childrens Hospital Foundation and the MCRI Infection and Immunity Theme, grants from the DHB Foundation and the Victorian Department of Jobs, Precincts and Regions. This work is supported by Victorian Governments Medical Research Operational Infrastructure Support Program.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Royal Children's Hospital Human Research Ethics CommitteeI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript ER -